Results of the multiple-treatments meta-analysis comparing different influenza 2009 H1N1 formulations.

Only randomized trials were included.*Numbers refer to doses of Hemagglutinin antigen in micrograms. Risk differences (RD), with their respective 95% credible intervals (CI), compared with a vaccine including 1.88–5.25 µg hemagglutinin antigen and non-aluminum adjuvants (baseline comparator). RD expresses the absolute difference in risk between the two groups that is attributable to the intervention—i.e., if the likelihood of seroconversion in the reference group is 0.80 and it is 0.50 in the experimental group, the risk difference will be 0.80−0.50 = 0.30. The baseline value for hemagglutination–inhibition is 83.4% after the first or single dose; 96.5% after two doses. Aluminum adjuvants were aluminum hydroxide or aluminum phosphate. Non-aluminum adjuvants were oil-in-water emulsions.本研究仅纳入随机对照试验。 *注：数值以微克（µg）为单位，代表血凝素抗原（Hemagglutinin antigen）的剂量。 风险差（Risk difference, RD）及其对应的95%可信区间（credible intervals, CI）以含1.88~5.25 µg血凝素抗原且搭配非铝佐剂的疫苗作为基线对照进行计算。 RD表示两组间由干预措施导致的风险绝对差值——即若参照组的血清阳转率为0.80，实验组为0.50，则风险差为0.80−0.50=0.30。 首剂或单剂接种后，血凝抑制试验的基线阳性率为83.4%；完成两剂接种后则升至96.5%。 铝佐剂包括氢氧化铝或磷酸铝。 非铝佐剂则为水包油型乳剂。